-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277-300
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
0021965806
-
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
-
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918-928
-
(1985)
Cancer
, vol.56
, pp. 918-928
-
-
Okuda, K.1
Ohtsuki, T.2
Obata, H.3
Tomimatsu, M.4
Okazaki, N.5
Hasegawa, H.6
Nakajima, Y.7
Ohnishi, K.8
-
4
-
-
9044233634
-
Results of 280 liver resections for hepatocellular carcinoma
-
Takenaka K, Kawahara N, Yamamoto K, Kajiyama K, Maeda T, Itasaka H, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K (1996) Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 131:71-76
-
(1996)
Arch Surg
, vol.131
, pp. 71-76
-
-
Takenaka, K.1
Kawahara, N.2
Yamamoto, K.3
Kajiyama, K.4
Maeda, T.5
Itasaka, H.6
Shirabe, K.7
Nishizaki, T.8
Yanaga, K.9
Sugimachi, K.10
-
5
-
-
33747830764
-
Hepatocellular carcinoma pathogenesis: From genes to environment
-
Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 674-687
-
-
Farazi, P.A.1
Depinho, R.A.2
-
6
-
-
47949116252
-
Sorafenib in advanced hepatocellular carcinoma
-
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
-
(2008)
N Engl J Med
, vol.359
, pp. 378-390
-
-
Llovet, J.M.1
Ricci, S.2
Mazzaferro, V.3
Hilgard, P.4
Gane, E.5
Blanc, J.F.6
De Oliveira, A.C.7
Santoro, A.8
Raoul, J.L.9
Forner, A.10
Schwartz, M.11
Porta, C.12
Zeuzem, S.13
Bolondi, L.14
Greten, T.F.15
Galle, P.R.16
Seitz, J.F.17
Borbath, I.18
Haussinger, D.19
Giannaris, T.20
Shan, M.21
Moscovici, M.22
Voliotis, D.23
Bruix, J.24
more..
-
7
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
8
-
-
4944234987
-
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma
-
Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST (2004) Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91:1354-1360
-
(2004)
Br J Surg
, vol.91
, pp. 1354-1360
-
-
Poon, R.T.1
Ho, J.W.2
Tong, C.S.3
Lau, C.4
Ng, I.O.5
Fan, S.T.6
-
9
-
-
0043163428
-
Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery
-
Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK, Lee SD (2003) Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10:355-362
-
(2003)
Ann Surg Oncol
, vol.10
, pp. 355-362
-
-
Chao, Y.1
Li, C.P.2
Chau, G.Y.3
Chen, C.P.4
King, K.L.5
Lui, W.Y.6
Yen, S.H.7
Chang, F.Y.8
Chan, W.K.9
Lee, S.D.10
-
10
-
-
33745220780
-
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
-
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS (2006) Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116:1582-1595
-
(2006)
J Clin Invest
, vol.116
, pp. 1582-1595
-
-
Kaposi-Novak, P.1
Lee, J.S.2
Gomez-Quiroz, L.3
Coulouarn, C.4
Factor, V.M.5
Thorgeirsson, S.S.6
-
11
-
-
44349155339
-
Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma
-
Osada S, Kanematsu M, Imai H, Goshima S (2008) Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology 55:544-549
-
(2008)
Hepatogastroenterology
, vol.55
, pp. 544-549
-
-
Osada, S.1
Kanematsu, M.2
Imai, H.3
Goshima, S.4
-
12
-
-
0345722740
-
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas
-
Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, Kim BJ, Bae JH, Hong YK, Lee KS, Lee SH, Yoo NJ, Jang JJ, Pack S, Zhuang Z, Schmidt L, Zbar B, Lee JY (1999) Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res 59:307-310
-
(1999)
Cancer Res
, vol.59
, pp. 307-310
-
-
Park, W.S.1
Dong, S.M.2
Kim, S.Y.3
Na, E.Y.4
Shin, M.S.5
Pi, J.H.6
Kim, B.J.7
Bae, J.H.8
Hong, Y.K.9
Lee, K.S.10
Lee, S.H.11
Yoo, N.J.12
Jang, J.J.13
Pack, S.14
Zhuang, Z.15
Schmidt, L.16
Zbar, B.17
Lee, J.Y.18
-
13
-
-
0027954225
-
C-met mRNA overexpression in human hepatocellular carcinoma
-
Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, Bartrons R (1994) c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19:88-91
-
(1994)
Hepatology
, vol.19
, pp. 88-91
-
-
Boix, L.1
Rosa, J.L.2
Ventura, F.3
Castells, A.4
Bruix, J.5
Rodes, J.6
Bartrons, R.7
-
14
-
-
0030951358
-
Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma
-
Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E (1997) Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25:619-623
-
(1997)
Hepatology
, vol.25
, pp. 619-623
-
-
Ueki, T.1
Fujimoto, J.2
Suzuki, T.3
Yamamoto, H.4
Okamoto, E.5
-
15
-
-
0027967963
-
Expression of the c-met protooncogene in human hepatocellular carcinoma
-
Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A (1994) Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20:1231-1236
-
(1994)
Hepatology
, vol.20
, pp. 1231-1236
-
-
Suzuki, K.1
Hayashi, N.2
Yamada, Y.3
Yoshihara, H.4
Miyamoto, Y.5
Ito, Y.6
Ito, T.7
Katayama, K.8
Sasaki, Y.9
Ito, A.10
-
16
-
-
0030857813
-
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas
-
Kiss A, Wang NJ, Xie JP, Thorgeirsson SS (1997) Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3:1059-1066
-
(1997)
Clin Cancer Res
, vol.3
, pp. 1059-1066
-
-
Kiss, A.1
Wang, N.J.2
Xie, J.P.3
Thorgeirsson, S.S.4
-
17
-
-
0035102323
-
Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo
-
Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, Schwall R, Ferrara N, Gerritsen ME (2001) Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 158:1111-1120
-
(2001)
Am J Pathol
, vol.158
, pp. 1111-1120
-
-
Xin, X.1
Yang, S.2
Ingle, G.3
Zlot, C.4
Rangell, L.5
Kowalski, J.6
Schwall, R.7
Ferrara, N.8
Gerritsen, M.E.9
-
18
-
-
0037478437
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
-
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361
-
(2003)
Cancer Cell
, vol.3
, pp. 347-361
-
-
Pennacchietti, S.1
Michieli, P.2
Galluzzo, M.3
Mazzone, M.4
Giordano, S.5
Comoglio, P.M.6
-
19
-
-
74549209715
-
Hepatocyte growth factor (HGF) is a prognostic biomarker for overall survival and a pharmacodynamic biomarker for sorafenib response in the SHARP phase III HCC trial
-
Sept 12-16, 2008, Stockholm, Sweden. Abstract #4600
-
Pena C, Shan M, Wilhelm S, Lathia C (2008) Hepatocyte growth factor (HGF) is a prognostic biomarker for overall survival and a pharmacodynamic biomarker for sorafenib response in the SHARP phase III HCC trial. 33rd European society for medical oncology (ESMO) congress, Sept 12-16, 2008, Stockholm, Sweden. Abstract #4600
-
(2008)
33rd European Society for Medical Oncology (ESMO) Congress
-
-
Pena, C.1
Shan, M.2
Wilhelm, S.3
Lathia, C.4
-
20
-
-
70149109569
-
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: Activation of AXL
-
Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM (2009) Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 69:6871-6878
-
(2009)
Cancer Res
, vol.69
, pp. 6871-6878
-
-
Liu, L.1
Greger, J.2
Shi, H.3
Liu, Y.4
Greshock, J.5
Annan, R.6
Halsey, W.7
Sathe, G.M.8
Martin, A.M.9
Gilmer, T.M.10
-
21
-
-
70350230210
-
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases
-
Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH (2009) Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 69:8009-8016
-
(2009)
Cancer Res
, vol.69
, pp. 8009-8016
-
-
Qian, F.1
Engst, S.2
Yamaguchi, K.3
Yu, P.4
Won, K.A.5
Mock, L.6
Lou, T.7
Tan, J.8
Li, C.9
Tam, D.10
Lougheed, J.11
Yakes, F.M.12
Bentzien, F.13
Xu, W.14
Zaks, T.15
Wooster, R.16
Greshock, J.17
Joly, A.H.18
-
22
-
-
77954236265
-
A phase i study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
-
Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM (2010) A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16:3507-3516
-
(2010)
Clin Cancer Res
, vol.16
, pp. 3507-3516
-
-
Eder, J.P.1
Shapiro, G.I.2
Appleman, L.J.3
Zhu, A.X.4
Miles, D.5
Keer, H.6
Cancilla, B.7
Chu, F.8
Hitchcock-Bryan, S.9
Sherman, L.10
McCallum, S.11
Heath, E.I.12
Boerner, S.A.13
Lorusso, P.M.14
-
23
-
-
33846812600
-
Xenografts of human hepatocellular carcinoma: A useful model for testing drugs
-
Huynh H, Soo KC, Chow PK, Panasci L, Tran E (2006) Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12:4306-4314
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4306-4314
-
-
Huynh, H.1
Soo, K.C.2
Chow, P.K.3
Panasci, L.4
Tran, E.5
-
24
-
-
71349084002
-
AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
-
Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Toh HC, Thng CH, Chow P, Ong HS, Chung A, Goh BC, Smith PD, Soo KC (2010) AZD6244 enhances the antitumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). J Hepatol 52:79-87
-
(2010)
J Hepatol
, vol.52
, pp. 79-87
-
-
Huynh, H.1
Ngo, V.C.2
Koong, H.N.3
Poon, D.4
Choo, S.P.5
Toh, H.C.6
Thng, C.H.7
Chow, P.8
Ong, H.S.9
Chung, A.10
Goh, B.C.11
Smith, P.D.12
Soo, K.C.13
-
25
-
-
0345601083
-
Met, metastasis, motility and more
-
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Natl Rev Mol Cell Biol 4(12):915-925
-
(2003)
Natl Rev Mol Cell Biol
, vol.4
, Issue.12
, pp. 915-925
-
-
Birchmeier, C.1
Birchmeier, W.2
Gherardi, E.3
Vande Woude, G.F.4
-
26
-
-
0038697632
-
How to make tubes: Signaling by the Met receptor tyrosine kinase
-
Rosario M, Birchmeier W (2003) How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 13:328-335
-
(2003)
Trends Cell Biol
, vol.13
, pp. 328-335
-
-
Rosario, M.1
Birchmeier, W.2
-
27
-
-
0026722243
-
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
-
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641
-
(1992)
J Cell Biol
, vol.119
, pp. 629-641
-
-
Bussolino, F.1
Di Renzo, M.F.2
Ziche, M.3
Bocchietto, E.4
Olivero, M.5
Naldini, L.6
Gaudino, G.7
Tamagnone, L.8
Coffer, A.9
Comoglio, P.M.10
-
28
-
-
57749189578
-
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
-
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
-
(2009)
Lancet Oncol
, vol.10
, pp. 25-34
-
-
Cheng, A.L.1
Kang, Y.K.2
Chen, Z.3
Tsao, C.J.4
Qin, S.5
Kim, J.S.6
Luo, R.7
Feng, J.8
Ye, S.9
Yang, T.S.10
Xu, J.11
Sun, Y.12
Liang, H.13
Liu, J.14
Wang, J.15
Tak, W.Y.16
Pan, H.17
Burock, K.18
Zou, J.19
Voliotis, D.20
Guan, Z.21
more..
-
29
-
-
58149175849
-
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma
-
Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14:6146-6153
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6146-6153
-
-
Huynh, H.1
Ngo, V.C.2
Fargnoli, J.3
Ayers, M.4
Soo, K.C.5
Koong, H.N.6
Thng, C.H.7
Ong, H.S.8
Chung, A.9
Chow, P.10
Pollock, P.11
Byron, S.12
Tran, E.13
-
30
-
-
79960408937
-
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer
-
You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT, McDonald DM (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71(14):4758-4768
-
(2011)
Cancer Res
, vol.71
, Issue.14
, pp. 4758-4768
-
-
You, W.K.1
Sennino, B.2
Williamson, C.W.3
Falcón, B.4
Hashizume, H.5
Yao, L.C.6
Aftab, D.T.7
McDonald, D.M.8
-
31
-
-
0024403228
-
Oncogene-induced liver neoplasia in transgenic mice
-
Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL (1989) Oncogene-induced liver neoplasia in transgenic mice. Oncogene 4:715-724
-
(1989)
Oncogene
, vol.4
, pp. 715-724
-
-
Sandgren, E.P.1
Quaife, C.J.2
Pinkert, C.A.3
Palmiter, R.D.4
Brinster, R.L.5
-
32
-
-
0027245446
-
Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: Interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis
-
Murakami H, Sanderson ND, Nagy P, Marino PA, Merlino G, Thorgeirsson SS (1993) Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res 53:1719-1723
-
(1993)
Cancer Res
, vol.53
, pp. 1719-1723
-
-
Murakami, H.1
Sanderson, N.D.2
Nagy, P.3
Marino, P.A.4
Merlino, G.5
Thorgeirsson, S.S.6
-
33
-
-
85047698718
-
Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors
-
Wu Y, Renard CA, Apiou F, Huerre M, Tiollais P, Dutrillaux B, Buendia MA (2002) Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors. Oncogene 21:1518-1526
-
(2002)
Oncogene
, vol.21
, pp. 1518-1526
-
-
Wu, Y.1
Renard, C.A.2
Apiou, F.3
Huerre, M.4
Tiollais, P.5
Dutrillaux, B.6
Buendia, M.A.7
-
34
-
-
7744220635
-
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
-
Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117
-
(2004)
Nature
, vol.431
, pp. 1112-1117
-
-
Shachaf, C.M.1
Kopelman, A.M.2
Arvanitis, C.3
Karlsson, A.4
Beer, S.5
Mandl, S.6
Bachmann, M.H.7
Borowsky, A.D.8
Ruebner, B.9
Cardiff, R.D.10
Yang, Q.11
Bishop, J.M.12
Contag, C.H.13
Felsher, D.W.14
-
35
-
-
14944350367
-
Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor
-
Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F (2005) Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105(5):1970-1976
-
(2005)
Blood
, vol.105
, Issue.5
, pp. 1970-1976
-
-
Gallicchio, M.1
Mitola, S.2
Valdembri, D.3
Fantozzi, R.4
Varnum, B.5
Avanzi, G.C.6
Bussolino, F.7
-
36
-
-
77954238997
-
Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184
-
Sennino B, Naylor RM, Tabruyn SP, You WK, Aftab DA, McDonald DM (2009) Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184. Mol Cancer Ther 8:A13
-
(2009)
Mol Cancer Ther
, vol.8
-
-
Sennino, B.1
Naylor, R.M.2
Tabruyn, S.P.3
You, W.K.4
Aftab, D.A.5
McDonald, D.M.6
-
37
-
-
78650339354
-
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib- resistant tumors
-
Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG (2010) HGF/c-Met acts as an alternative angiogenic pathway in sunitinib- resistant tumors. Cancer Res 70:10090-10100
-
(2010)
Cancer Res
, vol.70
, pp. 10090-10100
-
-
Shojaei, F.1
Lee, J.H.2
Simmons, B.H.3
Wong, A.4
Esparza, C.O.5
Plumlee, P.A.6
Feng, J.7
Stewart, A.E.8
Hu-Lowe, D.D.9
Christensen, J.G.10
-
38
-
-
0242331653
-
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation
-
Zhang YW, Su Y, Volpert OV, Vande Woude GF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100:12718-12723
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 12718-12723
-
-
Zhang, Y.W.1
Su, Y.2
Volpert, O.V.3
Vande Woude, G.F.4
-
39
-
-
60649116477
-
Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited
-
Loges S, Mazzone M, Hohensinner P, Carmeliet P (2009) Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 15:167-170
-
(2009)
Cancer Cell
, vol.15
, pp. 167-170
-
-
Loges, S.1
Mazzone, M.2
Hohensinner, P.3
Carmeliet, P.4
-
40
-
-
60649087564
-
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
-
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
-
(2009)
Cancer Cell
, vol.15
, pp. 232-239
-
-
Ebos, J.M.1
Lee, C.R.2
Cruz-Munoz, W.3
Bjarnason, G.A.4
Christensen, J.G.5
Kerbel, R.S.6
-
41
-
-
60649106195
-
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
-
Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231
-
(2009)
Cancer Cell
, vol.15
, pp. 220-231
-
-
Paez-Ribes, M.1
Allen, E.2
Hudock, J.3
Takeda, T.4
Okuyama, H.5
Vinals, F.6
Inoue, M.7
Bergers, G.8
Hanahan, D.9
Casanovas, O.10
-
42
-
-
44449151030
-
Drug development of MET inhibitors: Targeting oncogene addiction and expedience
-
Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7:504-516
-
(2008)
Nat Rev Drug Discov
, vol.7
, pp. 504-516
-
-
Comoglio, P.M.1
Giordano, S.2
Trusolino, L.3
|